{"id":"W4286294091","doi":"10.1200/jco.2022.40.16_suppl.tps8074","title":"MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Pfizer","keywords":"Daratumumab; Medicine; Lenalidomide; Internal medicine; Combination therapy; Oncology; Clinical endpoint; Pomalidomide; Phases of clinical research; Multiple myeloma; Regimen; Dexamethasone; Refractory (planetary science); Pharmacology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003315094,0.00259436,0.002523736,0.0006858155,0.0007777472,0.001524189,0.001518973,0.002418803,0.004924594],"category_scores_gemma":[0.001437173,0.001067195,0.002545343,0.0004708953,0.0015477,0.001574706,0.0006394497,0.004403814,0.001341221],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001581587,"about_ca_system_score_gemma":0.002244748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001524518,"about_ca_topic_score_gemma":0.003672298,"domain_scores_codex":[0.9990614,0.0005008893,0.00003849954,0.0001412292,0.00008199265,0.0001760417],"domain_scores_gemma":[0.9990059,0.0001444547,0.0002060257,0.00006037575,0.0000562765,0.0005269315],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.927072,0.04049207,0.002235991,0.0003792955,0.0009564505,0.0001049909,0.0001531576,0.0006295884,0.008688146,0.0001806622,0.001524938,0.01758269],"study_design_scores_gemma":[0.8606835,0.1342618,0.002737432,0.00001381275,0.0002794436,0.00005482536,0.00002911683,0.0005394873,0.0005465303,0.0001147618,0.0007194705,0.00001979264],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859372,0.002145665,0.0007859031,0.0009504377,0.0003557871,0.006584627,0.001351037,0.0001664552,0.001722903],"genre_scores_gemma":[0.9807796,0.001372328,0.002986252,0.002542434,0.0005139211,0.007017762,0.002129288,0.000046304,0.00261208],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004924594,"threshold_uncertainty_score":0.01753211,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07689841356222658,"score_gpt":0.4527453867881656,"score_spread":0.375846973225939,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}